Recent Advances in Glucocorticoid Receptor Action (Ernst Schering Research Foundation Workshop Vol.40) （2002. XXI, 376 p. w. 82 figs. (partly col.). 21,5 cm）

個数：

Recent Advances in Glucocorticoid Receptor Action (Ernst Schering Research Foundation Workshop Vol.40) （2002. XXI, 376 p. w. 82 figs. (partly col.). 21,5 cm）

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6～9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    【重要ご説明事項】
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版／ページ数 368 p.
  • 商品コード 9783540432296

Full Description

Since 1948, hydrocortisone (cortisol), the principal glucocorticoid (GC) of the human adrenal cortex has been successfully used at phar- macological concentrations for the suppression of clinical manifesta- tions of rheumatoid arthritis. Numerous compounds with GC activity have also been developed and used. Fifty years after their initial clinical use, GCs are still the most im- portant and frequently prescribed class of anti-inflammatory drugs for various inflammatory disorders. They are administered either orally, parenterally (intravenous, intramuscular, intrathecal), or topically (cu- taneous, intranasal, pulmonic, rectal). Despite the many beneficial ef- fects of GCs, they also have their limitations and disadvantages that occur with varying prevalence on different organs and after different durations of therapy. These side-effects can range in severity from cos- metic (e.g. telangiectasias, hypertrichosis) to seriously disabling (e.g. induction of glaucoma, diabetes, osteoporosis) or even life-threatening disorders (e.g. gastric haemorrhage). These adverse effects of GCs se- riously handicap their successful use as anti-inflammatory agents.
There is therefore a strong need for the development of substances with the anti-inflammatory potency of classical GCs but with reduced side-effects.

Contents

1 Glucocorticoids and Asthma.- 2 Immune Monitoring of Glucocorticoid Therapy.- 3 Topical Glucocorticoid Therapy in Dermatology.- 4 Bone Effects of Glucocorticoid Therapy.- 5 Corticosteroids in Ophthalmology.- 6 Special Problems in Glucocorticoid Treatment in Children.- 7 Functional Implications of Glucocorticoid Receptor Trafficking.- 8 The Dynamics of Intranuclear Movement and Chromatin Remodeling by the Glucocorticoid Receptor.- 9 Glucocorticoid Receptor Antagonism of AP-1 Activity by Inhibition of MAPK Family.- 10 Mast Cells as Targets for Glucocorticoids in the Treatment of Allergic Disorders.- 11 Cytosolic Glucocorticoid Receptor-Interacting Proteins.- 12 The Glucocorticoid Receptor ?-Isoform: A Perspective on Its Relevance in Human Health and Disease.- 13 Cooperation of Nuclear Transcription Factors Regulated by Steroid and Peptide Hormones.- 14 Induction and Repression of NF-?B-Driven Inflammatory Genes.- 15 DNA-Dependent Cofactor Selectivity of the Glucocorticoid Receptor.- 16 The Anti-inflammatory Action of Glucocorticoid Hormones.- 17 Analysis of Glucocorticoid Receptor Function in the Mouse by Gene Targeting.- 18 Glucocorticoid-Inducible Genes That Regulate T-Cell Function.- 19 Structural Analysis of the GR Ligand-Binding Domain.- 20 SEGRAs: A Novel Class of Anti-inflammatory Compounds.- Previous Volumes Published in This Series.